CL2022000937A1 - Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas - Google Patents
Variantes de nucleasas cas12a y métodos de preparación y uso de las mismasInfo
- Publication number
- CL2022000937A1 CL2022000937A1 CL2022000937A CL2022000937A CL2022000937A1 CL 2022000937 A1 CL2022000937 A1 CL 2022000937A1 CL 2022000937 A CL2022000937 A CL 2022000937A CL 2022000937 A CL2022000937 A CL 2022000937A CL 2022000937 A1 CL2022000937 A1 CL 2022000937A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- variants
- preparation
- nuclease variants
- cas12a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916392P | 2019-10-17 | 2019-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000937A1 true CL2022000937A1 (es) | 2023-01-20 |
Family
ID=75492833
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000937A CL2022000937A1 (es) | 2019-10-17 | 2022-04-13 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
| CL2024001737A CL2024001737A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
| CL2024001734A CL2024001734A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
| CL2024001733A CL2024001733A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001737A CL2024001737A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
| CL2024001734A CL2024001734A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
| CL2024001733A CL2024001733A1 (es) | 2019-10-17 | 2024-06-11 | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11866745B2 (enExample) |
| EP (1) | EP4045643A4 (enExample) |
| JP (2) | JP7644755B2 (enExample) |
| KR (1) | KR20220097408A (enExample) |
| CN (1) | CN114829595B (enExample) |
| AU (1) | AU2020366358A1 (enExample) |
| BR (1) | BR112022007125A2 (enExample) |
| CA (1) | CA3157707A1 (enExample) |
| CL (4) | CL2022000937A1 (enExample) |
| IL (1) | IL292117A (enExample) |
| MX (1) | MX2022004549A (enExample) |
| WO (1) | WO2021076682A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
| KR20260004568A (ko) * | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| AU2017302551B2 (en) | 2016-07-26 | 2023-04-27 | The General Hospital Corporation | Variants of CRISPR from Prevotella and Francisella 1 (Cpf1) |
| EP4291644A4 (en) * | 2021-02-12 | 2026-02-18 | Univ Leland Stanford Junior | CAS12A SYNTHETIC FOR IMPROVED MULTIPLEX GENE CONTROL AND EDITING |
| CN113136376B (zh) * | 2021-05-26 | 2022-10-21 | 武汉大学 | 一种Cas12a变体及其在基因编辑中的应用 |
| EP4399310A4 (en) * | 2021-09-08 | 2025-07-16 | Arbor Biotechnologies Inc | COMPOSITIONS COMPRISING A CRISPR NUCLEASE AND USES THEREOF |
| CN114214348A (zh) * | 2021-11-16 | 2022-03-22 | 河南农业大学 | 应用于核酸检测的Crispr/LbCas12a突变体蛋白及其制备方法和应用 |
| CN118339285A (zh) * | 2021-12-09 | 2024-07-12 | 北京干细胞与再生医学研究院 | 工程化Cas12b效应子蛋白及其使用方法 |
| CA3245296A1 (en) * | 2022-01-06 | 2023-07-13 | Ensoma Aps | CAS12A ENDONUCLEASE VARIANTS AND METHODS OF USE |
| EP4508205A1 (en) * | 2022-04-12 | 2025-02-19 | John Innes Centre | Compositions and methods for increasing genome editing efficiency |
| WO2023232109A1 (zh) * | 2022-06-01 | 2023-12-07 | 中国科学院遗传与发育生物学研究所 | 新的crispr基因编辑系统 |
| CN116286734B (zh) * | 2022-11-29 | 2024-04-02 | 武汉大学 | 野生型LbCas12a蛋白的突变体及SNP检测用途 |
| CN116144631B (zh) * | 2023-01-17 | 2023-09-15 | 华中农业大学 | 耐热型核酸内切酶及其介导的基因编辑系统 |
| AU2024229193A1 (en) * | 2023-03-01 | 2025-09-11 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| CN116410955B (zh) * | 2023-03-10 | 2023-12-19 | 华中农业大学 | 两种新型核酸内切酶及其在核酸检测中的应用 |
| CN116179512B (zh) * | 2023-03-16 | 2023-09-15 | 华中农业大学 | 靶标识别范围广的核酸内切酶及其应用 |
| AU2024309386A1 (en) | 2023-06-30 | 2025-12-18 | Christiana Care Gene Editing Institute, Inc. | Nras gene knockout for treatment of cancer |
| KR102789465B1 (ko) | 2023-09-20 | 2025-04-04 | 주식회사 엔세이지 | 신규 CRISPR/Cas12a 시스템 및 그 유전자 편집 용도 |
| CN119432813A (zh) * | 2023-12-29 | 2025-02-14 | 武汉艾迪晶生物科技有限公司 | Cas蛋白、组合蛋白、核酸分子、核糖核蛋白复合物、重组载体、转基因细胞及其应用 |
| CN117844782B (zh) * | 2024-03-06 | 2024-05-31 | 崖州湾国家实验室 | 靶向范围广的基因编辑核酸酶及其在核酸检测中的应用 |
| WO2025213016A2 (en) | 2024-04-04 | 2025-10-09 | Christiana Care Gene Editing Institute, Inc. | Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2 |
| WO2025226816A1 (en) | 2024-04-23 | 2025-10-30 | Christiana Care Gene Editing Institute, Inc. | Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes |
| WO2025244732A1 (en) * | 2024-05-24 | 2025-11-27 | The Regents Of The University Of California | Variant cas12a protein compositions and methods |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
| WO2026015427A1 (en) | 2024-07-08 | 2026-01-15 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of cas12a |
| CN119506250B (zh) * | 2024-11-29 | 2025-09-09 | 大连理工大学 | 一种多PAM选择的基因编辑系统NovaCas-2及其应用 |
| CN119876148B (zh) * | 2025-01-23 | 2025-10-17 | 中国科学技术大学 | Crispr rna突变体及其在基因编辑和核酸检测中的应用 |
| CN121653102B (zh) * | 2026-02-09 | 2026-07-24 | 武汉艾迪晶生物科技有限公司 | 一种Cas酶突变体及组合蛋白、核酸分子、重组载体、转基因细胞及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017106657A1 (en) * | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US20190264186A1 (en) * | 2016-01-22 | 2019-08-29 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
| KR20260004568A (ko) * | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| ES2919961T3 (es) * | 2016-04-21 | 2022-07-29 | Univ Kobe Nat Univ Corp | Método para aumentar la eficiencia de introducción de mutaciones en una técnica de modificación de secuencias genómicas, y complejo molecular para su uso en la misma |
| JP2019532644A (ja) * | 2016-09-30 | 2019-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｒｎａ誘導型核酸修飾酵素及びその使用方法 |
| IL306092A (en) * | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| WO2018195545A2 (en) * | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| EP3625342B1 (en) * | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| KR102678809B1 (ko) * | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| JP2019016859A (ja) | 2017-07-04 | 2019-01-31 | オリンパス株式会社 | 観察装置および観察方法 |
| AR114014A1 (es) * | 2017-12-22 | 2020-07-08 | Inst Genetics & Developmental Biology Cas | Sistema de edición de bases y método basado en proteína cpf1 |
| CA3088052A1 (en) * | 2018-01-11 | 2019-07-18 | KWS SAAT SE & Co. KGaA | Optimized plant crispr/cpf1 systems |
| CN108486146B (zh) * | 2018-03-16 | 2021-02-19 | 中国农业科学院作物科学研究所 | LbCpf1-RR突变体用于CRISPR/Cpf1系统在植物基因编辑中的应用 |
-
2020
- 2020-10-15 CN CN202080087121.8A patent/CN114829595B/zh active Active
- 2020-10-15 CA CA3157707A patent/CA3157707A1/en active Pending
- 2020-10-15 BR BR112022007125A patent/BR112022007125A2/pt unknown
- 2020-10-15 WO PCT/US2020/055659 patent/WO2021076682A1/en not_active Ceased
- 2020-10-15 KR KR1020227015955A patent/KR20220097408A/ko active Pending
- 2020-10-15 AU AU2020366358A patent/AU2020366358A1/en not_active Abandoned
- 2020-10-15 EP EP20875763.3A patent/EP4045643A4/en active Pending
- 2020-10-15 US US17/071,095 patent/US11866745B2/en active Active
- 2020-10-15 MX MX2022004549A patent/MX2022004549A/es unknown
- 2020-10-15 JP JP2022523132A patent/JP7644755B2/ja active Active
- 2020-10-15 IL IL292117A patent/IL292117A/en unknown
-
2022
- 2022-04-13 CL CL2022000937A patent/CL2022000937A1/es unknown
-
2023
- 2023-11-06 US US18/502,136 patent/US20240076639A1/en active Pending
- 2023-11-06 US US18/502,194 patent/US20240076640A1/en active Pending
-
2024
- 2024-06-11 CL CL2024001737A patent/CL2024001737A1/es unknown
- 2024-06-11 CL CL2024001734A patent/CL2024001734A1/es unknown
- 2024-06-11 CL CL2024001733A patent/CL2024001733A1/es unknown
-
2025
- 2025-02-27 JP JP2025030119A patent/JP2025087754A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11866745B2 (en) | 2024-01-09 |
| KR20220097408A (ko) | 2022-07-07 |
| CN114829595B (zh) | 2026-05-29 |
| JP2025087754A (ja) | 2025-06-10 |
| WO2021076682A1 (en) | 2021-04-22 |
| US20210115421A1 (en) | 2021-04-22 |
| JP2022552409A (ja) | 2022-12-15 |
| CL2024001733A1 (es) | 2024-11-15 |
| US20240076639A1 (en) | 2024-03-07 |
| MX2022004549A (es) | 2022-07-21 |
| EP4045643A4 (en) | 2023-11-08 |
| US20240076640A1 (en) | 2024-03-07 |
| BR112022007125A2 (pt) | 2022-07-05 |
| CN114829595A (zh) | 2022-07-29 |
| CL2024001734A1 (es) | 2024-11-15 |
| AU2020366358A1 (en) | 2022-04-28 |
| CL2024001737A1 (es) | 2024-11-15 |
| JP7644755B2 (ja) | 2025-03-12 |
| CA3157707A1 (en) | 2021-04-22 |
| IL292117A (en) | 2022-06-01 |
| NZ787124A (en) | 2025-09-26 |
| EP4045643A1 (en) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001734A1 (es) | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas | |
| CL2017000780A1 (es) | Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis b | |
| EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| EP3938379A4 (en) | HIV RNA VACCINE | |
| EP3532089A4 (en) | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF | |
| EP3408392A4 (en) | RNA-induced clearance of the human JC-virus and other polymorphs | |
| CL2019001066A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) | |
| MX2019011764A (es) | Composiciones limpiadoras y usos de las mismas. | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| MX2019014640A (es) | Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas. | |
| EP3407918A4 (en) | METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS | |
| BR112018067408A2 (pt) | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas | |
| UA124935C2 (uk) | Комбіноване лікування гематологічних ракових захворювань | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| AR111908A1 (es) | Composiciones terapéuticas y métodos de tratamiento de hepatitis b | |
| EA202190810A1 (ru) | Способы и наборы для получения цельной крови с инактивированным патогеном | |
| MX2018016037A (es) | Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa. | |
| EP3692155A4 (en) | PRODUCTION OF POLYHYDROXYBUTYRATE IN WOOD-LJUNGDAHL MICROORGANISMS | |
| WO2016164619A3 (en) | Compositions and methods for the treatment of hbv infection | |
| UY38733A (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
| MX2017008383A (es) | Preparación de n,n-(di)alquilaminoalquil(met)acrilamida o (met)acrilato de n,n-(di)alquilaminoalquilo y las sales de amonio cuaternario de las mismas como auxiliares de floculación y agentes gelificantes. | |
| CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
| BR112018009946A2 (pt) | pró-fármacos de ácido nucleico | |
| IL261516A (en) | Methods and compositions for increased double stranded rna production |